CME/CE: Warfarin: Double-Edged Sword After PE

Publication Date:
Sat, 08/01/2015
By: Alere Staff

SPONSORED BY

MedPage Today

American Heart Association

 

ACTIVE DATE

July 7, 2015 – July 7, 2017

 

CREDIT

Physicians: 0.25 AMA PRA Category 1 Credit(s) ™

 

DESCRIPTION

After a first-time, unprovoked pulmonary embolism, an additional 18 months of warfarin, beyond the initial 6-month therapy, reduced the risk of a major event compared with placebo though the risk of major bleeding persisted, researchers found.

 

LINK

http://www.medpagetoday.com/Cardiology/VenousThrombosis/52477